Geoffrey Gilmartin, MD
Geoffrey S. Gilmartin, MD is a pulmonary disease specialist and an attending physician in the intensive care unit at Beth Israel Deaconess Medical Center and formerly served as director of the Beth Israel Deaconess Sleep Disorders Center and on its pulmonary leadership team. Additionally, he has held many leadership positions in the life sciences industry. Currently, he serves as Global Product Leader at AstraZeneca. From August 2016 to August 2020, Dr. Gilmartin worked as Chief Development Officer at Proteostasis Therapeutics, Inc. (PTI) before transitioning to the role of Chief Medical Officer. From January 2014 to August 2016, he held positions of increasing responsibility at AstraZeneca including Senior Medical Lead in the global medicines development for the benralizumab Phase 3 program in severe asthma. From January 2011 to January 2014, he held positions of increasing responsibility at Vertex Pharmaceuticals Incorporated including serving as medical lead for the Kalydeco® (ivacaftor) clinical development program, spearheading the initiation of Phase 3 trials to support label expansion studies for the drug.
Dr. Gilmartin received a BA in history from Dartmouth College, a MD from Brown University Warren Alpert School of Medicine and a MMSc from Harvard Medical School. He completed his residency at Beth Israel Deaconess.